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Background: Epidemiological studies have suggested the benefits of omega-3 polyunsaturated fatty acids (n-3
PUFAs) on cardiovascular health, but only limited data are available describing n-3 PUFA regulated pathways in
humans. The aim of this study was to investigate the effects of n-3 PUFA administration on whole genome
expression profiles in the blood of normo- and dyslipidemic subjects.
Methods: Differentially expressed genes were detected after four hours, one week and twelve weeks of
supplementation with either fish oil (FO) or corn oil in normo- and dyslipidemic men using whole genome microarrays.
Results: Independent of the oil, a significantly higher number of genes was regulated in dyslipidemic subjects compared
to normolipidemic subjects. Pathway analyses discovered metabolisms dominantly affected by FO after twelve weeks of
supplementation, including the lipid metabolism, immune system and cardiovascular diseases. Several pro-inflammatory
genes, in particular, were down-regulated in dyslipidemic subjects, indicating the immune-modulatory and
anti-inflammatory capability of FO and its bioactive FAs, eicosapentaenoic acid and docosahexaenoic acid.
Conclusions: This is the first study showing significant differences in gene expression profiles between normo- and
dyslipidemic men after FO supplementation. Further studies need to clarify the exact role of n-3 PUFAs in pathways and
metabolisms which were identified as being regulated after FO supplementation in this study.
Trial registration: ClinicalTrials.gov (ID: NCT01089231)
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Numerous epidemiologic and intervention studies have
shown the beneficial effects of fish oil (FO) and its princi-
pal omega-3 poly unsaturated fatty acids (n-3 PUFAs), ei-
cosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic
acid (DHA, 22:6n-3), in the prevention of atherosclerosis
and cardiovascular diseases (CVD) [1-3]. EPA and DHA
are known to affect the lipid profile by reducing the ele-
vated triacylglycerol (TG) level and increasing the high
density lipoprotein (HDL) level [4,5]. Due to the effects
on lipid levels, subjects with dyslipidemia, especially* Correspondence: Schuchardt@nutrition.uni-hannover.de
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reproduction in any medium, provided the orhypertriglyceridemia, benefit from FO supplementation to
reduce the cardiovascular risk [6-8].
Beyond the positive effects on lipid levels, other cardio-
protective effects of EPA and DHA are known involving
anti-inflammation, modulation of cardiac ion channels, in-
fluence on membrane microdomains and downstream cell
signaling pathways, anti-thrombotic and anti-arrhythmic
effects, induction of hemodynamic changes, and improve-
ment of endothelial function [9,10]. The underlying mo-
lecular mechanisms by which EPA and DHA exert these
beneficial effects on cardiovascular health are not com-
pletely understood. It is believed that many effects of n-3
PUFAs are mediated by interferences with signaling trans-
duction pathways [11].
N-3 PUFAs are known to affect a myriad of molecular
pathways, including the regulation of gene expressionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or by their secondary metabolites, for example, eicosa-
noids. It is known that n-3 PUFAs induce changes in the
expression of several genes related to lipid and carbohy-
drate metabolism, cell differentiation and growth, cytokine,
adhesion, and eicosanoid production, as well as oxidative
and immune system processes [13-15]. The inhibition of in-
flammatory signaling, observed in in vitro and animal stud-
ies, is viewed as one of the major mechanisms on how n-3
PUFAs may improve cardiovascular health [11]. However,
the anti-inflammatory effect of n-3 PUFAs has not been
completely confirmed in human subjects [10].
Only a few human studies have investigated genome-
wide expression changes after FO supplementation to iden-
tify specific metabolic pathways. Bouwens and co-workers
analyzed the effects of FO supplementation on whole gen-
ome expression changes and performed several pathway
analyses which mainly showed a down-regulation of genes
involved in inflammatory and stress-related pathways [16].
Another study monitored the expression changes of 588
genes after FO supplementation and discovered a regulative
effect in several lymphocyte functions such as signaling,
cell cycle, cytokine production, and apoptotic and stress
response [17].
To our knowledge, gene expression profiles in re-
sponse to FO supplementation have not been investigated
in dyslipidemic subjects so far. Connections between
dyslipidemia, especially hypertriglyceridemia and HDL-
hypercholesterolemia, and chronic inflammation have
already been uncovered [18]. The discovery of specific
FO metabolic pathways which are influenced by FO
in dyslipidemic states may provide insights into the anti-
inflammatory and lipid-lowering effects of n-3 PUFAs. In
addition, it is not known if normo- and dyslipidemic sub-
jects display different gene expression profiles in response
to FO supplementation. Accordingly, we conducted a nu-
trition study to identify the differences in gene expression
profiles after FO supplementation between normo- and
dyslipidemic subjects.
Methods
A randomized, double-blind, controlled, parallel inter-
vention study of three months duration was undertaken.
This investigator-initiated study was designed and con-
ducted according to the principles of the Good Clinical
Practice Guidelines laid down in the Declaration of
Helsinki. The study was registered at ClinicalTrials.gov
(ID: NCT01089231).
Subjects
The recruitment of subjects was performed by several
advertisements and study placards in Hannover. One
hundred and six subjects were pre-selected via telephone
interviews according to the following exclusion criteria:Female; body-mass-index>35; smoker; intake of any
corticosteroid, lipid-lowering or anti-inflammatory drugs;
diagnosed chronic - cardiovascular - or liver diseases;
gastrointestinal disorders; blood coagulation disorders and
intake of coagulation-inhibiting drugs (e.g. Marcumar);
renal failure; periodic intake of laxatives; ingestion of sup-
plements enriched with n-3 PUFAs, phytosterols, polyglu-
cosamines, other lipid-binding ingredients, or daily eating
of fatty fish; allergy to fish or FO; or participation in another
clinical study<30 days before the start of the study or at
the same time. The pre-selected subjects were invited for a
screening examination to collect fasting blood and deter-
mine serum lipid levels. Among these subjects, 20 normoli-
pidemic men (total cholesterol (TC)<200 mg/dl; low
density lipoprotein (LDL)<130 mg/dl; TG<150 mg/dl)
and 20 dyslipidemic men (TC>200 mg/dl; LDL>130 mg/
dl; TG>150 mg/ml), aged between 29 and 51 years, were
enrolled in the study population (Figure 1). All subjects
included gave their written informed consent to take part
in the study, which was approved by the Freiburger ethics
committee.
Study design
The 20 normolipidemic and the 20 dyslipidemic subjects
were subdivided into two groups. Thus, a total of four
groups with ten men per group passed through the study.
The formation of groups was performed by stratified allo-
cation according to each subject’s age to realize a compar-
able mean age between the groups. The four study groups
were randomly assigned to different study products by an
uninvolved collaborator. Subjects ingested either six FO
or six corn oil (CO) capsules per day for a period of twelve
weeks. The daily n-3 PUFA intake via FO capsules was
2.7 g (1.14 g DHA and 1.56 g EPA). The predominant FA
of the CO capsules was the omega-6 (n-6) PUFA linoleic
acid (LA, 18:2n-6). Thus, the daily LA intake via CO
capsules was 3.05 g LA. The subjects were instructed to
ingest the capsules together with food, three in the morn-
ing and three in the evening, and to maintain their usual
exercise and dietary habits throughout the intervention
time. As an exception, on the first intervention day, all six
capsules were ingested at the same time in the morning
after a standardized breakfast. Fasting blood samples were
collected by venepuncture during each visit. Additionally,
participants completed a questionnaire to obtain informa-
tion about changes in medication, diet (e.g. changes in
weekly fish intake, preferred fish dishes or species, re-
spectively) and lifestyle habits (e.g. physical activity), as
well as the tolerability of the capsules.
Determination of fasting serum lipids and red blood cell
(RBC) membrane fatty acid (FA) composition
Fasting venous blood samples were collected in BD
VacationerW Blood Collection Tubes (Becton Dickinson,
Figure 1 Flow chart of subject recruitment and sample selection for microarray analysis.
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determined by an external contract laboratory (LADR,
Hannover; Germany) at baseline (t0), after one week (t1)
and after twelve weeks (t12) of supplementation. RBC
membrane FA composition including the omega-3
index, given as EPA and DHA, was analyzed at t0 and
t12 according to the omega-3 index methodology [19].
Results are presented as a percentage of the total FAs
identified after response factor correction. The coeffi-
cient of variation for EPA and DHA was 5%. Quality was
assured according to DIN ISO 15189.
Statistical analysis of blood levels
Statistical analysis of clinical parameters was processed
with SPSS software version 17 (SPSS Inc., Chicago, IL,
USA). The results are based on per protocol population,
defined as subjects completing all visits not infringing
the study protocol, and are presented as mean± SD
(Table 1). Differences between t0 and t12 were tested
within the groups by t-test for dependent samples.
Group differences were examined with a two-factor vari-
ance analysis (ANOVA) combined with a post hoc test
of contrast (Scheffé). Additionally, differences between
groups were analyzed by covariance analysis (ANCOVA)
using the corresponding baseline values as covariates to
detect possible effects caused by diverse baseline values.
Statistical significance was generally accepted at p<0.05.
Microarray analyses
Sample collection
Fasting venous blood samples were collected in PAX-
gene Blood RNA Tubes (PreAnalytiX, Hombrechtikon,Switzerland) at baseline (t0), after one week (t1), and
after twelve weeks (t12) of supplementation to analyze
medium- and long-term effects of the FO and CO sup-
plementation on gene expression regulation. For short-
term effects, venous blood samples were collected four
hours (t4h) after the first intake of the capsules. The time
point of four hours was selected in accordance with
results achieved in a previous study where the strongest
postprandial gene expression changes in peripheral
blood mononuclear cells of healthy men were observed
after four and six hours [20]. The whole blood samples
collected were incubated for 24 hours in the PAXgene
Blood RNA Tubes at room temperature.
Total RNA isolation from human whole blood and RNA
purification
The total RNA was isolated with the PAXgene Blood
RNA Kit (PreAnalytiX, Hombrechtikon, Switzerland),
according to the manufacturer’s recommended proce-
dures. RNA yield was quantified by Nanodrop ND-1000
spectrophotometer (peQLab Biotechnologie GmbH,
Erlangen, Germany) measurement. Total RNA was puri-
fied with the Globin Clear Kit (Ambon, Applied Bios
stems, Darmstadt, Germany), according to the manu-
facturer’s instructions. The reduction of highly abun-
dant globin mRNA transcripts in whole blood samples is
necessary to enable the detection of low-abundance
transcripts [21]. The purified RNA was quantified
again, and the quality was measured with an Agilent
2100 Bioanalyzer using RNA 6000 Nano Chips and a
RNA 6000 Nano Kit (Agilent Technologies, Böblingen,
Germany).
Table 1 Anthropometric data, serum lipid levels and red blood cell membrane fatty acid composition of the four treatment groups (FO-N, CO-N, FO-D, CO-D)
at baseline (t0) and after supplementation with fish oil or corn oil over twelve weeks (t12)
Parameters FO-N (n= 10) CO-N (n= 7) CO-D (n = 8) FO-D (n = 9)
t0 t12 t0 t12 t0 t12 t0 t12
Age [years] 37.50 ± 8.11 37.40 ± 8.30 41.80 ± 8.94 40.20 ± 8.64
Body height [cm] 180.30 ± 6.29 181.60 ± 7.54 182.80 ± 7.02 180.40 ± 7.55
Body weight [kg] 78.90 ± 15.25 78.51 ± 16.13 85.80 ± 10.90 84.79 ± 11.19 85.50 ± 14.80 84.53 ± 14.51 94.80 ± 13.20 94.06 ± 13.80
Body mass index
[kg/m2]
24.20 ± 4.15 c 24.13 ± 4.50 25.90 ± 2.83 25.67 ± 2.78 25.40 ± 2.91 25.14 ± 2.86 29.00 ± 2.98 c 28.82 ± 3.25
TC [mg/dl] 184.10 ± 13.30 c 195.60 ± 26.10 194.00 ± 22.20 d 188.90 ± 21.50 261.00 ± 48.10 d 257.50 ± 60.30 262.20 ± 61.90 c 264.40 ± 49.20
TG [mg/dl] 82.40 ± 35.30 c 66.20 ± 16.70 A 155.60 ± 53.80 87.40 ± 14.80 A 175.00 ± 56.20 186.90 ± 49.60 322.40 ± 258.9 c 230.80 ± 147.0 }_T
HDL [mg/dl] 59.00 ± 10.40 c 65.20 ± 14.40 }_T 52.70 ± 12.70 52.60 ± 11.60 47.90 ± 10.02 47.40 ± 8.21 B 45.20 ± 6.50 c 50.80 ± 9.43 }B
LDL [mg/dl] 108.70 ± 12.80 c_T 117.20 ± 22.10 118.10 ± 25.10 d 118.60 ± 28.20 178.10 ± 45.40 d 172.60 ± 54.40 B_T 146.10 ± 5.31 c_T 167.40 ± 23.60 }_T B_T
LDL/HDL quotient 1.89 ± 0.40 c 1.88 ± 0.54 2.41 ± 0.89 d 2.41 ± 0.98 3.74 ± 0.68 d 3.60 ± 0.73 3.20 ± 0.58 c 3.24 ± 0.73
LA (18:2n-6) [%]* 0.25 ± 0.03 0.19 ± 0.03 } 0.23 ± 0.03 0.20 ± 0.05 0.22 ± 0.03 0.18 ± 0.05 0.23 ± 0.03 0.17 ± 0.03 }
AA (20:4n-6) [%]* 15.95 ± 0.81 c 13.00 ± 0.65 }a 15.74 ± 1.48 15.99 ± 1.74 a 14.94 ± 1.47 14.88 ± 1.22 b 12.82 ± 2.19 c 11.98 ± 1.61 b
EPA (22:5n-3) [%]* 2.31 ± 0.41 3.74 ± 0.51 }a 2.31 ± 0.22 2.44 ± 0.18 a 2.09 ± 0.41 2.39 ± 0.35 }b 2.00 ± 0.43 3.31 ± 0.26 }b
DHA (22:6n-3) [%]* 4.39 ± 0.68 6.87 ± 0.78 }a 4.16 ± 1.14 4.09 ± 0.94 a 4.28 ± 1.27 4.57 ± 1.10 b 3.90 ± 1.42 6.59 ± 0.75 }b
Omega-3-index
[%]*
5.24 ± 0.70 10.70 ± 1.06 }aA 5.08 ± 1.41 4.78 ± 1.16 aA 5.27 ± 1.69 5.50 ± 1.57 bB 4.90 ± 1.80 9.84 ± 1.26 }bB
* percentage of total fatty acids.
} P<0.05 (Changes between baseline and month three were evaluated within groups by Student’s t test for dependent samples).
a P<0.05 (Changes of means were evaluated between FO-N and CO-N by Student’s t test).
b P<0.05 (Changes of means were evaluated between FO-D and CO-D by Student’s t test).
c P<0.05 (Changes of means were evaluated between FO-N and FO-D by Student’s t test).
d P<0.05 (Changes of means were evaluated between CO-N and CO-D by Student’s t test).
A P<0.05 (Changes of means were evaluated between FO-N and CO-N group by ANCOVA using baseline as covariate).
B P<0.05 (Changes of means were evaluated between FO-D and CO-D group by ANCOVA using baseline as covariate).
_T trend of significance (P<0.1).
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Equal amounts of purified RNA samples from each
member of the respective group were pooled together.
This was done for all different time points (t0, t4h, t1,
and t12). Therefore, four pool-samples were generated by
this process for each group, which results in a total of
sixteen pool-samples for the microarray experiments.
This approach was chosen to reduce biological inter-
individual variability, which is frequent due to variations
in relative proportions of specific blood cell subsets, gen-
der, age, and disease state [22].
cDNA synthesis and hybridization
First-strand cDNA synthesis and tyramine signal amplifi-
cation (TSA) were performed using MicromaxTM TSATM
Labeling and Detection Kit (Perkin Elmer Life Sciences,
Rodgau, Germany) with several protocol modifications. A
total amount of 6 μg from every RNA pool, as well as
random hexamers primer (Ferment as, St. Leon-Rot,
Germany) and oligo dT primer (Roth, Karlsruhe, Germany),
were used for the cDNA synthesis, which was facilitated
by using Superscript III reverse transcriptase (Invitrogen,
Karlsruhe, Germany). The incubation time of two hours
was split into two one hour incubations and additional
Superscript III was added after first hour. Each RNA pool
was synthesized into two different labeled cDNAs,
fluorescein-labeled and biotin-labeled cDNA.
After labeling, the cDNA samples were purified with the
QIAquick PCR Purification Kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. Furthermore,
the cDNA samples were first vacuum-dried and then
resolved in hybridization buffer (4 x SSPE; 2.5 x Denhardt’s
reagent; 30% form amid). After a final degradation step
(3 minutes, 95°C), one-tenth of top-block (Sigma-Aldrich,
Steinheim, Germany) was added. Equal amounts of biotin-
labeled cDNA and fluorescein-labeled cDNA were hybri-
dized simultaneously in one experiment to human whole
genome One Array™ Microarrays (Phalanx Biotech Group;
Belmont, CA, USA). Hybridizations were carried out over-
night at 42°C in hybridization chambers (Eppendorf AG,
Hamburg, Germany).
After hybridization, unbound and non-specifically
fixed cDNA was removed by stringent washing from the
array. Specifically bound fluorescein- and biotin-labeled
cDNA were sequentially detected with a series of conju-
gate reporter molecules according to the TSA process,
ultimately with tyramide-Cy3 and tyramide-Cy5. Micro-
array experiments were performed for each study group
in a loop design (Figure 2) to save microarrays and pre-
vent dye-dependent variety effects [23].
Microarray data analysis
Microarrays were scanned several times with a 4000 B
scanner (Axon Instruments, Inc., Union City, CA, USA)and images were quantified using GenePixPro 6.0 Soft-
ware. The average pixel intensity within each spot was
determined and a local background was computed for
each spot. Net signal was determined by subtracting
local background from the average intensity. Signals not
consistently detectable (background corrected signal
lower than two times background standard deviation)
were excluded from further analysis. Following the pri-
mary analysis, data from different scans had to be sum-
marized. The scans first had to be normalized by the
sum of all corresponding spot-intensities due to different
laser power and photomultiplier-tube settings. After-
wards, data from different scans for each individual spot
could be averaged by the mean. The mean of the data
for differently labeled targets for each gene on two
microarrays was taken. It was assumed that the distribu-
tion of the pre-processed data was normal and hence, a
standard two-state pooled-variance t-test (1% and 5%
probability of error) was applied in order to detect dif-
ferentially expressed genes. Array data were submitted
to Gene Expression Omnibus (GEO) which supports
minimum information about a microarray experiment
(MIAME) [24]. The accession number of the submitted
dataset is GSE34898. Genes that were detected as differ-
entially expressed between baseline and measurement
time point (t4h, t1 or t12) were subjected to pathway ana-
lysis by the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database [25].
Results
Subject characteristics
At baseline, no significant differences of the mean age,
mean weight and the content of EPA and DHA in RBC
membranes, as well as in the omega-3 index, were
observed between all groups. However, comparison of
both FO groups showed that the dyslipidemic FO group
had a 4.8 kg/m2 higher BMI, higher TC and TG level,
lower HDL level, a higher LDL/HDL ratio, and a lower
arachidonic acid (AA, 20:4n-6) content in RBC mem-
branes than the normolipidemic FO group (Table 1).
Comparisons of both CO groups showed higher LDL and
TC levels, as well as a higher LDL/HDL ratio, in the dysli-
pidemic CO group than in the normolipidemic CO group.
All 40 subjects (20 normolipidemic and 20 dyslipidemic
men) completed the study. However, it was necessary to ex-
clude the RNA samples of ten subjects from the microarray
experiments and data analysis due to several reasons: Low
RNA yield (four subjects), consumption of alcohol with
effects on serum TG levels (two subjects), consumption of
medication that lead to exclusion (three subjects), and
highly elevated TG level (> 1000 in one subject). Therefore,
RNA pools were generated and data were analyzed from
nine (FO-N), six (CO-N), eight (CO-D), and seven (FO-D)
subjects for each investigation time point (Figure 1).
Figure 2 Loop-Design of microarray experiments.
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membranes and omega-3 index
The effects of the supplementation with either FO or
CO in normo- and dyslipidemic subjects on serum lipids
and FA composition of RBC membranes are shown in
Table 1. Blood lipids showed only slight differences be-
tween t0 and t12. A significant increase in HDL levels
was observed in the FO-D group, whereas a tendency
for increased HDL levels was seen in the FO-N group.
Furthermore, trends for an increased LDL and decreased
TG level were observed in the FO-D group. Comparison
of the t12 values between the FO and CO groups with a
covariance analysis (ANCOVA) using t0 values as covari-
ates, showed lower TG levels in the FO-N group than in
the CO-N group and higher HDL levels, as well as a
trend of lower LDL levels, in the FO-D group than in
the CO-D group.
Several significant differences could be observed in the
FA composition of RBC membranes and the omega-3
index between the groups. Within both FO groups, the
percentage of EPA and DHA, as well as the omega-3
index in RBC membranes, significantly increased after
twelve weeks of supplementation (p<0.001). Addition-
ally, the FO-N group showed a significant decrease of
the percentage of AA and LA in RBC membranes.
Within both CO groups, no statistical differences be-
tween t0 and t12 values could be detected, except the in-
crease of the percentage of EPA in RBC membranes in
the CO-D group. Group comparisons of the t12 values
between the FO and CO groups showed significantly
higher percentages of EPA, DHA and omega-3 index, as
well as lower percentages of AA in RBC membranes in
both the FO-N and FO-D group in comparison to the
respective CO groups.
Microarray analyses
Number of regulated genes
The total number of regulated genes of each study group
was determined and compared between groups. Both
dyslipidemic study groups showed a higher number of
regulated genes than normolipidemic study groups, in-
dependent of the type of supplemented oil (Figure 3).The differences in the total number of regulated genes
between the two CO groups are small, whereas both FO
groups showed substantial differences. A further deter-
mination of the direction of regulated genes in total
within each group discovered a higher number of down-
regulated genes in both dyslipidemic groups (CO-D and
FO-D). In contrast, a higher number of up-regulated
genes were observed in both normolipidemic groups
(CO-N and FO-N). Another observation was made con-
cerning the pattern of up- and down-regulated genes
within each group depending on the time point of inves-
tigation. Whereas the pattern of up- and down-regulated
genes was similar at the first two early time points (t4h
and t1), the pattern changed into the opposite direction
after twelve weeks of supplementation (t12). This obser-
vation was made in all groups, except the FO-D group.
Pathway analyses
Pathway analysis of the regulated genes were performed
for each group and time point. All pathways with regu-
lated genes were attributed to processes according to the
KEGG database (metabolism; genetic information pro-
cessing, environmental information processing, cellular
processes, organismal systems and human diseases) [25]
to analyze the influence of the supplemented oil type on
gene expression changes in different processes. Further-
more, the number of regulated genes in pathways
belonging to different processes was determined for each
group and compared as a percentage of total regulated
genes between groups. Thus, the influence of the supple-
mented oil type on different processes could be investi-
gated. Table 2 shows processes where a higher number
of genes in both FO groups were regulated at the differ-
ent time points compared to the corresponding CO
groups. It was noticeable that the lipid metabolism was
regulated at all time points after FO supplementation. A
greater number of processes were regulated in both FO
groups after twelve weeks (t12), including, for example,
lipid metabolism, the immune system and cardiovascular
diseases.
Further analyses concentrated on the long-term effects
after twelve weeks of FO supplementation (t12). Therefore,
Figure 3 Number of regulated genes. Number of genes that were regulated in the normolipidemic fish oil group (FO-N), normolipidemic corn
oil group (CO-N), dyslipidemic corn oil group (CO-D), and dyslipidemic fish oil group (FO-D) after four hours (t4h), one week (t1) and twelve weeks
(t12) of supplementation. Total regulated genes summarize all genes regulated during the different time points, without doubles, respectively.
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exemplary processes that were dominantly regulated in
both FO groups after twelve weeks (lipid metabolism, the
immune system, cardiovascular diseases) were selected
and listed for the FO-D group in Table 3. In some path-
ways of the lipid metabolism, genes were mainly down-
regulated (FA synthesis,-metabolism and elongation, AA-,
LA- and alpha linolenic acid metabolism), whereas in
others pathways, genes were mainly up-regulated (glycero-
lipid and glycerophospholipid metabolism). The immune
system-related pathway of complement and coagulation
cascade, as well as the two pathways related to cardiovas-
cular diseases, showed mainly down-regulated genes.
Generally, the majority of regulated genes in all groups
were detected in pathways related to the immune system. It
is known that FO supplementation provokes immune-
modulatory and anti-inflammatory effects. Therefore, regu-
lated genes related to inflammation and immune response,
were individually selected for the FO-D group to show the
direction of regulation (Table 4). This examination showed
that a greater number of pro-inflammatory genes were
down-regulated after twelve weeks of supplementation,
while a higher number of immune response related genes
were up-regulated. However, roughly the same number of
anti-inflammatory genes was up- and down-regulated.Discussion
It is known from numerous in vitro and in vivo studies
that FO and its general n-3 PUFAs, EPA and DHA,
regulate the expression of genes, but human interven-
tion studies investigating the effect of FO on whole gen-
ome gene expression are lacking. Our study aimed to
investigate two main objectives: The first intention was
to investigate the effects of FO supplementation on gene
expression changes in dyslipidemic subjects in compari-
son to normolipidemic subjects. The second objective
was to compare the effects of FO with CO, which is used
as placebo in many intervention studies, investigating
the physiological effects of FO. To the best of our know-
ledge, this is the first randomized intervention study
disclosing gene expression profiles on the whole genome
level under these specific conditions. In general, we
anticipated regulative effects of FO on the expression of
genes associated with the immune system and the lipid
metabolism, especially in dyslipidemic subjects.
Serum lipid and omega-3 index levels
As expected, the FO supplementation of dyslipidemic
subjects was followed by an increase in HDL levels and
a decrease in TG levels after twelve weeks, although not
significant due to the low group size. There was little or
Table 2 Selected processes dominantly regulated in dys- and normolipidemic subjects in response to fish oil
supplementation for four hours (t4h), one week (t1) and twelve weeks (t12) compared to corn oil supplementation
t4h t1 t12
Cell Communication Carbohydrate Metabolism Amino Acid Metabolism
Cell Growth and Death Cardiovascular Diseases Biosynthesis of Other
Circulatory System Circulatory System Secondary Metabolites
Digestive System Digestive System Cardiovascular Diseases
Endocrine System Energy Metabolism Cell Growth and Death
Excretory System Folding, Sorting and Endocrine System
Folding, Sorting and Degradation Energy Metabolism
Degradation Lipid Metabolism Excretory System
Immune System Signal Transduction Immune System
Lipid Metabolism Signalling Molecules and Immune System Diseases
Nervous System Interaction Lipid Metabolism
Signalling Molecules and Interaction Xenobiotics Biodegradation and Metabolism Metabolic Diseases
Metabolism of Cofactors and Vitamins
Metabolism of Other Amino Acids
Nervous System
Nucleotide Metabolism
Sensory System
The selection was performed as follows: The number of regulated genes within pathways was counted for each group. Pathways were assigned to corresponding
processes and the number of regulated genes in these pathways was summed up. The resulting data represent the number of regulated genes in different
processes for each group. These numbers were compared between groups and those processes were selected where both fish oil treatment groups (FO-D, FO-N)
showed more regulated genes compared with the corn oil treatment groups (CO-D, CO-N).
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after FO or CO supplementation. The omega-3 index
increased significantly in both FO treatment groups
from levels ~ 5% to levels of ~10% after twelve weeks of
supplementation, which is a shift from an unfavorable
area in view of the cardiovascular risk to optimal levels
of 8% or greater [26]. Moreover, the omega-3 index
increased in all subjects of the two FO groups, indicating
an efficient uptake and subsequent incorporation of EPA
and DHA in tissue membranes. It can, therefore, be
assumed that changes observed in gene expression in
the FO supplementation groups are the result of the
treatment.
Normolipidemic vs. dyslipidemic subjects
Gene expression profiles of normo- and dyslipidemic sub-
jects differed substantially after FO supplementation. In the
dyslipidemic study group, considerably more genes were
regulated after FO supplementation, whereas genes were
mainly down-regulated. Although the reason for this find-
ing cannot be clarified here, it might be partly explained by
the interrelation between inflammation and dyslipidemia
[18]. Several studies have demonstrated that a dyslipidemic
– in particular hypertriglyceridemic – state is accompanied
by an induction of pro-inflammatory pathways [27,28],
while n-3 PUFAs are known to suppress these pathways
[9]. Indeed, a number of pro-inflammatory genes weredown-regulated in dyslipidemic subjects after FO supple-
mentation, including members of the TNFα pathway. How-
ever, besides the regulated genes involved in inflammatory
pathways, it is apparent that a large number of other genes
were regulated in dyslipidemic subjects in response to FO
treatment, suggesting a strong regulative effect of FO in
people with dyslipidemia. It needs to be clarified in future
studies if some of these genes are associated with the
known beneficial effects FO or n-3 PUFAs in dyslipidemia.
In contrast to dyslipidemic subjects, a higher number
of genes were up-regulated in normolipidemic subjects
in response to FO supplementation. This finding corre-
sponds with the outcomes of two intervention studies
investigating the effect of FO supplementation on whole
genome expression in healthy subjects [16,17]. The study
of Gorjão and co-workers was conducted with ten men
aged between 25 and 45 years supplemented with 1.62 g
DHA and 0.78 g EPA per day over a period of eight
weeks. The design of this study is comparable with our
study, except for the sample material used for RNA iso-
lation (fractionated lymphocytes vs. whole blood). Differ-
ent RNA sources could yield different expression
patterns, and cell fractioning itself could alter the gene
expression pattern [29]. Nevertheless, both studies pro-
vided similar results. Gorjão and co-workers discovered
71 up- and 6 down-regulated genes by macroarray ana-
lysis. Our normolipidemic FO group showed 627 total
Table 3 Selected pathways and genes dominantly regulated in dyslipidemic subjects (FO-D) in response to fish oil
supplementation for twelve weeks
Pathway Gene name Gene symbol Entrez_ID Ratio t12 : t0
Lipid metabolism Fatty acid
biosynthesis
acetyl-CoA carboxylase beta ACACB 32 -4.67
Fatty acid elongation
in mitochondria
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA
thiolase/enoyl-CoA hydratase (trifunctional protein),
alpha subunit
HADHA 3030 -3.70
hydroxyacyl-CoA dehydrogenase HADH 3033 -2.34
Fatty acid metabolism enoyl-CoA delta isomerase 2 ECI2 10455 -4.54
enoyl-CoA delta isomerase 1 ECI1 1632 6.02
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA
thiolase/enoyl-CoA hydratase (trifunctional protein),
alpha subunit
HADHA 3030 -3.70
hydroxyacyl-CoA dehydrogenase HADH 3033 -2.34
acyl-CoA dehydrogenase, short/branched chain ACADSB 36 -13.69
aldehyde dehydrogenase 2 family (mitochondrial) ALDH2 217 3.26
Glycerolipid
metabolism
1-acylglycerol-3-phosphate O-acyltransferase 6 AGPAT6 137964 2.67
diacylglycerol kinase, alpha 80 kDa DGKA 1606 2.47
diacylglycerol kinase, eta DGKH 160851 -3.05
diacylglycerol kinase, theta 110 kDa DGKQ 1609 3.40
aldehyde dehydrogenase 2 family (mitochondrial) ALDH2 217 3.26
monoacylglycerol O-acyltransferase 3 MOGAT3 346606 -3.48
Glycerophospholipid
metabolism
1-acylglycerol-3-phosphate O-acyltransferase 6 AGPAT6 137964 2.67
phospholipase B1 PLB1 151056 11.68
diacylglycerol kinase, alpha 80 kDa DGKA 1606 2.47
diacylglycerol kinase, eta DGKH 160851 -3.05
diacylglycerol kinase, theta 110 kDa DGKQ 1609 3.40
phospholipase A2, group IIE PLA2G2E 30814 2.51
phosphatidylserine synthase 1 PTDSS1 9791 -2.84
Arachidonic acid
metabolism
phospholipase B1 PLB1 151056 11.68
gamma-glutamyltransferase 5 GGT5 2687 7.98
glutathione peroxidase 3 (plasma) GPX3 2878 -2.15
glutathione peroxidase 5 GPX5 2880 -2.41
phospholipase A2, group IIE PLA2G2E 30814 2.51
Linoleic acid
metabolism
phospholipase B1 PLB1 151056 11.68
phospholipase A2, group IIE PLA2G2E 30814 2.51
Alpha-linolenic acid
metabolism
phospholipase B1 PLB1 151056 11.68
phospholipase A2, group IIE PLA2G2E 30814 2.51
Immune system Complement and
coagulation cascades
complement component (3b/4b) receptor 1 CR1 1378 -3.37
coagulation factor III (thromboplastin, tissue factor) F3 2152 -4.23
fibrinogen gamma chain FGG 2266 -12.30
serpin peptidase inhibitor, clade C (antithrombin),
member 1
SERPINC1 462 3.23
Cardiovascular
diseases
Arrhythmogenic right
ventricular
cardiomyopathy
(ARVC)
desmocollin 2 DSC2 1824 -2.50
calcium channel, voltage-dependent, gamma
subunit 5
CACNG5 27091 -9.92
integrin, alpha 3 ITGA3 3675 -4.32
transcription factor 7-like 1 TCF7L1 83439 -4.93
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Table 3 Selected pathways and genes dominantly regulated in dyslipidemic subjects (FO-D) in response to fish oil
supplementation for twelve weeks (Continued)
Dilated
cardiomyopathy
adenylate cyclase 7 ADCY7 113 -2.13
calcium channel, voltage-dependent, gamma
subunit 5
CACNG5 27091 -9.92
integrin, alpha 3 ITGA3 3675 -4.32
myosin, light chain 2, regulatory, cardiac, slow MYL2 4633 2.68
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244 down-regulated. Therefore, both studies indicate
that genes in normolipidemic subjects are mainly up-
regulated after FO supplementation. In the study by
Bouwens and colleagues, a total of 111 men and woman
aged between 66 and 80 years were supplemented with
1.09 g EPA and 0.85 g DHA per day over 26 weeks.
There were great differences in the study design com-
pared to our study with regard to gender (men and
woman vs. men), subject age (older vs. middle aged),
daily n-3 PUFAs intake (1.94 g vs. 2.7 g/d EPA+DHA),
and sample material used for RNA isolation (peripheral
blood mononuclear cells vs. whole blood), which makes
it difficult to compare the results. However, the number
of total regulated genes in both studies was in the same
order of magnitude. Bouwens and co-workers identified
a total of 1040 regulated genes, with 537 up-regulated
and 503 down-regulated genes.
Fish oil vs. Corn oil
CO serves as placebo in many FO supplementation stud-
ies based on the assumption that CO is inert without bio-
logical effects. However, CO is rich in the n-6 PUFA LA, a
precursor for AA. Thus, CO similarly contains FAs, cap-
able of directly regulating gene expression or serving as
precursors for other bioactive lipid mediators which regu-
late gene expression. It was, therefore, our intention to en-
lighten the possible regulative effects of CO on gene
expression. The administration of six CO capsules pro-
vided three grams of LA per day, which is less than a
quarter of the usual dietary intake of LA, and considerably
less than a high consumption of vegetable oil. In view of
this small amount and the low conversion rate of LA to
AA, we assumed that the effect of LA on gene expression
would be infinitesimal. Surprisingly, our data revealed that
the administration of even small amounts of LA caused
changes in gene expression patterns. However, during the
evaluation of the study data, we focused on the specific
effects of FO on gene expression.
Our data demonstrated substantial differences in gene
expression regulation between FO and CO supplementa-
tion. Pathway analysis showed that considerably more
pathways were dominantly regulated in the FO groups
compared to the CO groups (in both normolipidemic
and dyslipidemic subjects). Additionally, significantlymore genes in these pathways and metabolisms were
shown to be regulated in dyslipidemic subjects after FO
supplementation compared to normolipidemic subjects,
suggesting a more pronounced regulative potential of
FO in dyslipidemic subjects. Metabolisms that were
dominantly affected by FO include, for example, the
immune system, lipid metabolism and CVD.
Immune system metabolism
Both FO and CO administration resulted in the regula-
tion of genes associated with the immune system and in-
fectious diseases, which is expected in view of the RNA
source used. RNA was isolated from whole blood, in-
cluding leukocytes, which are mainly involved in the im-
mune system and pathogen defense. Therefore, it is not
surprising that a great number of regulated genes are
involved in immune system related pathways. However,
comparing the effect of FO and CO supplementation on
the expression of immune system related genes, it appears
that FO regulates significantly more genes in specific path-
ways compared to CO, indicating the immune-modulatory
capability of FO and its bioactive FAs, EPA and DHA. Gen-
erally, EPA and DHA have anti-inflammatory properties by
increasing the production of potent bioactive lipid media-
tors (protecting and resolving), and inhibiting the formation
of n-6 FA-derived pro-inflammatory eicosanoids (e.g. pros-
taglandine E2 and Leukotriene B4) [30]. Together, these
effects directly or indirectly suppress the activity of nuclear
transcription factors, such as nuclear factor kappa b, which
controls the expression of a variety of pro-inflammatory
and pro-atherogenic genes, including those encoding for
interleukin (IL)-1, IL-6, IL-8, tumor necrosis factor alpha
(TNFα), E-selecting, vascular cell adhesion molecule-1, and
cyclooxygenase-2 [11,30].
With a few exceptions, our data revealed that none of
the key regulators mentioned above were regulated after
FO supplementation, either in dyslipidemic or in normoli-
pidemic subjects (IL-8 was down-regulated after one week
and twelve weeks in dyslipidemic FO-supplemented sub-
jects, as well as IL-1 receptor, type II after one week).
However, a number of inflammation and immune re-
sponse related genes were regulated after twelve weeks of
FO supplementation, especially in dyslipidemic subjects.
The ratios demonstrate that more pro-inflammatory genes
were down-regulated than up-regulated, whereas the rate
Table 4 Selection of inflammation and immune response related genes regulated in dyslipidemic subjects after
supplementation with fish oil for twelve weeks
Gene name Gene symbol Entrez_ID Ratio t12 : t0
Pro-inflammatory genes
Nitric oxide synthase, inducible NOS2 4843 -4.77
C-C chemokine receptor type 3 CCR3 1232 -4.49
Tumour necrosis factor receptor superfamily member 18 Precursor TNFRSF18 8784 -2.07
Interleukin-31 receptor A Precursor IL31RA 133396 -4.74
72 kDa type IV collagenase Precursor MMP2 4313 -6.16
Interleukin-8 Precursor IL8 3576 -5.67
Tumour necrosis factor receptor superfamily member 5 Precursor CD40 958 -4.72
Interleukin-2 receptor subunit beta Precursor IL2RB 3560 -3.22
Interleukin-3 receptor subunit alpha Precursor IL3RA 3563 -2.22
Stromelysin-1 Precursor MMP3 4314 -2.17
C-C motif chemokine 5 Precursor CCL5 6352 2.24
CD97 antigen Precursor CD97 976 2.26
Prostaglandin D2 receptor PTGDR 5729 4.47
Integrin alpha-L Precursor ITGAL 3683 5.07
Arachidonate 5-lipoxygenase-activating protein (FLAP) ALOX5AP 241 6.97
Anti-inflammatory genes
C-X-C motif chemokine 11 Precursor CXCL11 6373 -2.98
NF-kappa-B-repressing factor NKRF 55922 -82.11
NF-kappa-B inhibitor-like protein 2 NFKBIL2 4796 -3.30
Cytokine receptor-like factor 1 Precursor CRLF1 9244 -3.07
Lipopolysaccharide-induced tumour necrosis factor-alpha factor LITAF 9516 3.06
Interferon regulatory factor 1 IRF1 3659 3.16
Interferon-alpha/beta receptor alpha chain Precursor IFNAR1 3454 5.13
Suppressor of cytokine signalling 6 SOCS6 9306 6.01
Immune response related genes
Suppressor of cytokine signalling 2 SOCS2 8835 -6.05
Disintegrin and metalloproteinase domain-containing protein 10 Precursor ADAM10 102 -5.23
A disintegrin and metalloproteinase with thrombospondin motifs 10 Precursor ADAMTS10 81794 -3.14
Nitric oxide synthase, endothelial NOS3 4846 -2.55
SL cytokine Precursor FLT3LG 2323 -2.46
Prostaglandin E2 receptor EP3 subtype PTGER3 5733 -2.21
CD99 antigen-like protein 2 Precursor CD99L2 83692 2.18
Cytokine receptor common gamma chain Precursor IL2RG 3561 2.85
Monocyte differentiation antigen CD14 Precursor CD14 929 2.88
Chemokine-like factor (C32) CKLF 51192 11.73
T-cell surface glycoprotein CD3 delta chain Precursor CD3D 915 7.65
Tumour necrosis factor receptor superfamily member 1B Precursor TNFRSF1B 7133 2.51
B-lymphocyte antigen CD20 MS4A1 931 2.12
Interleukin-31 receptor A Precursor IL31RA 133396 5.72
Intercellular adhesion molecule 3 Precursor ICAM3 3385 5.85
CD320 antigen Precursor CD320 51293 8.17
CD2 antigen cytoplasmic tail-binding protein 2 CD2BP2 10421 8.77
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Table 4 Selection of inflammation and immune response related genes regulated in dyslipidemic subjects after
supplementation with fish oil for twelve weeks (Continued)
T-cell antigen CD7 Precursor CD7 924 2.30
C-C chemokine receptor-like 2 (Putative MCP-1 chemokine receptor) CCRL2 9034 17.55
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inflammatory genes. Moreover, pathway analyses showed
that genes of the complement and coagulation cascades
(complement component [3b/4b] receptor 1, coagulation
factor III [thromboplastin, tissue factor], fibrinogen
gamma chain) were mainly down-regulated in dyslipi-
demic subjects supplemented with FO. Since the blood
coagulation cascade is evolutionarily closely related to the
innate immune response, its pathways are assigned to the
immune system. The coagulation pathway is essential for
clot formation and the prevention of excessive bleeding. A
dysregulation of the cascade activities can result in clinical
manifestations of several diseases with critical thrombotic
and/or inflammatory complications [31]. Our results
underline the well-known effect of FO to diminish the co-
agulant activity by the lowering of several coagulation fac-
tors and by reducing the capability of plasma to support
thrombin generation, especially in patients with hyperlip-
idemia [32].
Lipid metabolism
As expected, pathway analyses revealed that the effect of
FO supplementation on the expression of genes involved
in lipid metabolism was more pronounced compared to
CO. Similarly, the regulatory effect of FO supplementa-
tion was markedly stronger among dyslipidemic subjects
compared to normolipidemic subjects relating to the
number of regulated genes. The liver plays a central role
in lipid metabolism and n-3 PUFAs have been shown to
regulate hepatic gene expression by targeting several
transcriptional regulatory networks [9]: For example, n-3
PUFAs regulate several inflammation molecules, includ-
ing serum amyloid A, TNFα and IL-6 [33]. These in-
flammation mediators modulate the expression of many
lipid metabolism-related genes, for example, by suppres-
sing the expression of perilipin, sterol regulatory element
binding protein-1 and lipoprotein lipase. Together, these
regulatory pathways result in induced lipolysis and
reduced lipogenesis [33]. Besides the down-regulation of
FA synthesis gene expression, n-3 PUFAs up-regulate
gene expression involved in FA oxidation, which is trig-
gered by an activation of the transcription factor peroxi-
some proliferator activated receptors alpha (PPARα) [9].
Again, none of the lipid metabolism-related genes men-
tioned above were regulated in the present study after
12 weeks of supplementation, probably because the com-
partment examined (whole blood) is inappropriate to re-
flect the transcriptional profile of the liver. However, FOsupplementation provoked a regulation of several lipid
metabolism-associated pathways in dyslipidemic subjects
in contrast to normolipidemic subjects, where only a few
genes were regulated. This finding emphasizes the regulat-
ing effect of n-3 PUFAs on the lipid metabolism in dyslipi-
demic conditions. Genes, for example, in pathways related
to FA metabolism and FA elongation in mitochondria, in-
cluding genes coding several enzymes, were mainly down-
regulated in FO supplemented dyslipidemic subjects.
These enzymes (several dehydrogenises and an isomerase)
are mainly promoters of mitochondrial FA oxidation. This
down-regulation is in contrast to studies, which showed
an increased peroxisomal FA oxidation in rats in response
to FO administration, while the effect of FO on mitochon-
drial ß-oxidation was inconsistent [34]. The observed
reduced FA oxidation after 12 weeks of FO treatment in
this study may be the result of increasing levels of oxidized
n-3 PUFAs, which are prone to oxidation. Subsequently,
the resulting oxidative stress may lead to an induction of
antioxidative mechanisms, which in turn reduce oxidation.
The finding that PPARα was up-regulated one week after
FO capsule ingestion in dyslipidemic subjects (data not
shown) support this hypothesis.
We observed a down-regulation of the gene coding for
acetyl-CoA carboxylase beta, which is one of the key
enzymes in FA biosynthesis, indicating a reduced lipogen-
esis. This finding may partly explain the reduced TG levels
observed in this study. In the same group, several genes in
pathways involved in FA metabolism were regulated.
Interestingly, genes coding for Phospholipase A2, group
IIE (PLA2G2E), a member of the secreted Phospholipase
A2 [sPLA2] family) and Phospholipase B1 (PLB1) were
up-regulated. The regulatory functions of PLA2G2E have
not been completely uncovered. It is known that
PLA2G2E catalyzes the hydrolysis of the 2-acyl groups in
3-sn-phosphoglycerides in membranes and could promote
inflammation, since the release of AA is the first step in
the AA breakdown pathway, which can be metabolized to
several inflammatory and thrombogenic eicosanoids
(prostaglandines and Leukotrienes) by the activity of
cyclooxygenase and lipoxygenase [35]. The up-regulation
of PLA2G2E observed could also point to an intensified
exchange of membrane bound AA in favor of EPA and
DHA, which is indeed reflected in the decrease in AA
levels and concomitant increase in EPA and DHA levels
in RBC membranes observed.
In addition, an up-regulation of several genes related to
glycerolipid metabolism was observed in FO supplemented
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nents of membranes and an up-regulation of the glyceroli-
pid metabolism indicates remodeling activities of the
membrane. Finally, several genes of the glycerophospholi-
pid metabolism were up-regulated in FO supplemented
dyslipidemic subjects. Glycerophospholipids, also referred
to as phospholipids, are key components of the lipid bilayer
of biological membranes and constitute the binding site for
EPA and DHA, which are integrated in the membrane. An
up-regulation of the glycerophospholipid metabolism
results in an increased de novo phospholipid biosynthesis,
enabling the incorporation of EPA and DHA into the mem-
brane [36].
CVD metabolism
Pathway analysis showed that FO supplementation induced
the regulation of pathways involved in specific CVD related
metabolisms, especially among dyslipidemic subjects. Sev-
eral genes from pathways involved in arrhythmogenic right
ventricular cardiomyopathy (ARVC) and dilated cardiomy-
opathy (DCM) were mainly down-regulated. ARVC and
DCM belong to cardiomyopathies, a group of diseases that
primarily affect the myocardium. While ARVC is character-
ized by a fibro-fatty replacement of right ventricle myocar-
dium, DCM is a myocardial disease with dilated left
ventricle myocardium impairing the systolic pump function
of the heart. ARVC and DCM may cause ventricular
tachyarrhythmias, blood clots or sudden death. Although
the aetiopathogenesis, including the role of dyslipidemia in
ARVC and DCM, is largely unknown [37], inflammatory
processes are likely to be involved [38,39]. The down-
regulating effect of FO on genes involved in ARVC and
DCM pathways observed may be the result of diverse regu-
latory effects on lipid metabolism and anti-inflammatory
processes. However, the effect of n-3 PUFA supplementa-
tion on the pathogenesis of ARVC and DCM in humans is
unknown. An animal study showed that FO supplementa-
tion reduces arrhythmia in boxers (Canis lupus) with
ARVC [40]. In a recent intervention study with non-
ischemic DCM patients, it was shown that n-3 PUFA treat-
ment increased left ventricle systolic function and func-
tional capacity [41].
Strengths and limitations
Strengths: The methodological approach of this study
was carefully elaborated. The use of whole blood for
RNA isolation is advantageous in view of the easy sam-
ple collection and the prevention of altered gene expres-
sion patterns which emerge during cell fractionation
steps [29]. In addition, the pooling of RNA samples
reduces inter-individual variation, enabling one to focus
on the characteristics of a population in contrast to an
individual level [42]. Moreover, only men were enrolled
in the study population. Women are subjected to severalhormonal changes which involve individual gene expres-
sion changes and hamper the attribution of observed
effects to treatment.
Limitations: The study has a number of potential lim-
itations, for example, the small sample size. Moreover,
nine subject samples had to be excluded from micro-
array analysis. To minimize the already high effort for
the participants, it was desisted from obtaining multiple
baseline samples, which is recommended due to heavy
fluctuations in lipid – especially TG – levels. The effect
of FO on gene expression was compared to CO, which
is often used in n-3 PUFA supplementation studies as a
placebo control. It would have been instructive to exam-
ine the gene expression of a third untreated study group.
However, this additional expenditure would have gone
beyond the scope of our study.
Conclusion
This is the first study showing significant differences in
gene expression profiles between normo- and dyslipi-
demic subjects after FO supplementation. Dyslipidemic
subjects presented substantially more regulated genes
and pathways, which were mainly down-regulated. Sev-
eral of the pathways that were especially regulated in
dyslipidemic subjects in response to FO supplementation
are related to the immune system, inflammation, lipid
metabolism, and CVD. In particular, several genes
involved in FA metabolism were down-regulated, em-
phasizing the regulating effect of n-3 PUFA on the lipid
metabolism in dyslipidemic conditions. Further studies
combining genetic with physiological endpoints need to
clarify the mechanisms by which n-3 PUFAs trigger gene
regulation and affect various regulatory networks. The
disentanglement of such interferences may also explain
the beneficial effects of n-3 PUFAs on dyslipidemia, ath-
erosclerosis and CVD in many experimental models and
clinical conditions.
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